Background and aims: Optimal treatment of infections caused by Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila requires antibiotics with intracellular activity. Linezolid accumulates poorly within cells. Torezolid (TR-700) is a novel methyltetrazolyl oxazolidinone with potentially different cellular pharmacokinetic properties. Our aim was to examine the accumulation and intracellular activities of torezolid in this context. Results: Torezolid accumulated rapidly in THP-1 macrophages, reaching a stable intracellular to extracellular ratio of 10 (compared with 1-2 for linezolid) within 15 min. On a weight concentration basis (mg/L), torezolid was 5-to 10-fold more potent intracellularly (lower concentration needed to achieve a bacteriostatic effect) than linezolid against phagocytosed S. aureus, L. monocytogenes and L. pneumophila, with no change in maximal efficacy (1 log 10 reduction of the original, post-phagocytosis inoculum). When drugs were compared at equipotent concentrations (multiples of the MIC), no difference was seen between linezolid and torezolid, but the higher potency of torezolid allowed control of intracellular infections caused by linezolid-resistant S. aureus.
Introduction
The cellular and tissue accumulation of antibiotics has been the subject of a large number of studies, but its importance for activity against intracellular bacteria remains controversial. 1 -6 Studies examining a series of antibiotics belonging to the main pharmacological classes (with several derivatives within each class) have convincingly shown that accumulation per se may not be predictive of efficacy. 7 Thus, antibiotics belonging to a pharmacological class known for its low accumulation level, such as b-lactams, are not necessarily inactive against intracellular forms of susceptible bacteria as demonstrated for Listeria monocytogenes or even Staphylococcus aureus. 8, 9 Conversely, macrolides are considerably less potent than fluoroquinolones against the same organisms, 10 -12 even though their cellular accumulation is much higher. There are, however, other situations, such as observed with the lipoglycopeptides telavancin and oritavancin, in which structural changes made in comparison with vancomycin result in a higher accumulation and a commensurately higher intracellular activity. 11, 13 It is therefore important to experimentally assess the intracellular accumulation and activity of novel drugs individually, in order to obtain a clear description of their behaviour in this context.
Torezolid (TR-700) is a novel methyltetrazolyl oxazolidinone, with enhanced activity against Gram-positive cocci including linezolid-non-susceptible strains, 14, 15 owing to additional target site interactions. 16 Linezolid accumulates in only modest amounts in eukaryotic cells and displays a low level of activity (mostly static) against phagocytosed S. aureus (including strains of clinical origin).
7, 17 The structure of torezolid (see Figure 1 ) suggests different cellular pharmacokinetic properties compared with linezolid. In the present study, we have examined: (i) the cellular pharmacokinetics of torezolid and linezolid in THP-1 macrophages and their pharmacodynamics in cells infected with S. aureus (this model has been designed and validated for this type of study, 7 and macrophages represent a first line of defence against a variety of staphylococcal infections 18 ); (ii) pharmacodynamic properties of both oxazolidinones were also studied with human endothelial cells [human umbilical vein endothelial cells (HUVECs)] since adhesion and invasion by S. aureus in vascular endothelium is probably an important aspect in the persistent and relapsing character of endocarditis; 19 and (iii) the experiments were then extended to L. monocytogenes and Legionella pneumophila, as these organisms develop in different subcellular compartments than S. aureus and provide us, therefore, with a broader view of the parameters governing the activity of intracellular antibiotics.
Materials and methods

Antibiotics and main reagents
Torezolid was obtained as microbiological standard from Trius Therapeutics (San Diego, CA, USA). The other antibiotics were obtained as the clinical products for intravenous administration to humans and complying with the European Pharmacopoeia [gentamicin as GEOMYCINE w (distributed in Belgium by GlaxoSmithKline, Genval); and linezolid as ZYVOXID w (distributed in Belgium by Pfizer, Brussels)]. Cell culture media and sera were from Invitrogen (Carlsbad, CA, USA) and Lonza (Basel, Switzerland).
Cell lines
Experiments were performed with: (i) human THP-1 cells (ATCC TIB-202; American Tissue Culture Collection, Manassas, VA, USA), a myelomonocytic cell line displaying macrophage-like activity maintained in our laboratory as previously described; 7 and (ii) HUVECs (Lonza, Walkersville, MD, USA). The latter were handled as follows. Cells were maintained in endothelial growth medium (EGM) and 25 cm 2 gelatin-coated flasks as described in the manufacturer's instructions, and used before the eighth passage. For each experiment, cells having reached $80% confluency were removed from flasks by use of 0.05% trypsin/EDTA, washed in Dulbecco's modified Eagle's medium (DMEM)-glutamax medium supplemented with 10% fetal calf serum (FCS; for trypsin inactivation) and seeded into 12-well gelatin-coated plates in EGM. Monolayers were obtained after $3-4 days. The day prior to S. aureus cell invasion assays, the medium was removed and cells were washed with phosphate-buffered saline (PBS) to ensure complete removal of the antibiotics present in EGM and transferred to DMEM-glutamax medium (Invitrogen) supplemented with 10% FCS.
Accumulation and assay of cell-associated antibiotics
Uninfected THP-1 macrophages were used for these studies as the lack of radiolabelled drug forced us to use extracellular concentrations (!10 mg/L) that would have prevented the intracellular growth of the bacteria. Cells were incubated with the drugs for the appropriate duration (with or without the inhibitors under study) and collected after thorough washing with pre-warmed PBS and gentle pelleting. 7 For experiments evaluating the influence of the pH and the temperature of the culture medium, cells were resuspended in RPMI 1640 medium (supplemented with 10% FCS) adjusted to the specific pH (7.4 or 5.5) or temperature (37 or 48C) values for 2 h before addition of the drug under study, and the corresponding pH or temperature value was maintained throughout the experiment until cell collection. Torezolid and linezolid were assayed by the disc-plate method, using S. aureus ATCC 25923 as a test organism as described previously 7, 9 [typical values for the lowest limit of detection, 2 and 8 mg/L; typical linear response between 2 and 500 and 16 and 500 mg/L for torezolid and linezolid, with correlation coefficients (R 
S. aureus cell invasion and intracellular growth
For both THP-1 macrophages and HUVECs, invasion by S. aureus was performed as follows. Bacterial cultures were centrifuged at 14 000 rpm for 10 min, and the pelleted bacteria resuspended and incubated for 30 min at 378C in RPMI 1640 medium supplemented with 10% fresh human serum (Lonza) to allow for opsonization. Opsonized bacteria were then added to the cell culture medium of either THP-1 macrophages of HUVECs at an initial ratio of four bacteria per cell and maintained for 1 h at 378C, after which extracellular bacteria were removed by washing. Cells were then re-incubated for 24 h in the presence of the antibiotics under study (or in the presence of gentamicin at half its MIC for controls, to minimize growth of extracellular bacteria). Cell viability was tested at the end of each critical experiment by Trypan Blue staining (,10% stained cells).
Bacterial strains and susceptibility testing Table 1 shows the strains used in our study. MIC determinations were made in Mueller -Hinton broth ( pH 7.3, 24 h) for S. aureus, in tryptic soy broth ( pH 7.4, 24 h) for L. monocytogenes, and in a-ketoglutarate buffered yeast extract broth ( pH 6.9, 48 h) for L. pneumophila.
Determination of extracellular and intracellular activities
For S. aureus, extracellular activities were measured in MuellerHinton broth; intracellular activities were determined towards bacteria phagocytosed by either THP-1 macrophages or HUVECs following the general procedures described in detail in our earlier publication 7 (typical starting inocula: $1-2Â10 6 cfu per mL (broth) or per mg of cell protein (cells)]. For other bacteria, infection of THP-1 cells and assessment of the intracellular activity of antibiotics were performed as described previously for L. monocytogenes, 9 with minor adaptations for L. pneumophila using a starting inoculum of 10 bacteria per macrophage, and exposing the cells to 50 mg/L gentamicin for 30-45 min after phagocytosis for elimination of adherent, non-internalized bacteria. As discussed previously, 20 the large dilutions of the cellular material made during its collection and actual spread on plates ensured absence of interference with cfu counts by the presence of carried-over antibiotics. 
Curve fitting and statistical analyses
Results
Cellular accumulation of torezolid and linezolid by THP-1 cells
In the first series of experiments we investigated whether torezolid and linezolid could be differentiated with respect to accumulation by macrophages and influence of pH and temperature. Figure 2 (a) shows that torezolid accumulated very quickly, reaching cellular concentrations $10-to 15-fold the extracellular concentration within 15 min (or less), whereas linezolid reached a cellular concentration similar to the extracellular concentration after $1 h. Both antibiotics, however, showed $50% impairment in their accumulation when incubated at 48C (Figure 2b ). In contrast, the accumulation of torezolid was drastically reduced (.90%) when cells were incubated at pH 5.5 in comparison with pH 7.4, whereas the accumulation of linezolid was reduced by only 60% (Figure 2c ). These changes were not due to alteration of cell viability, as Trypan Blue exclusion assays did not show meaningful differences between control and treated cells (,10% stained cells for all conditions). Table 1 shows the MICs of torezolid and linezolid for the strains used in this study. Torezolid showed consistently lower MICs (2 -5 dilutions) than linezolid for all linezolid-susceptible strains, and maintained a low MIC ( 1 mg/L) against the linezolid-resistant S. aureus strains [MIC . 4 mg/L; European Bacteria in broth or infected THP-1 macrophages and HUVECs were exposed for 24 h to a wide range of concentrations of torezolid or linezolid (from $0.01 to 100Â the MIC) to determine the overall shape of the response. Data are summarized together in Figure 3 (with the corresponding pertinent regression parameters shown in Table 2 ). In all cases, antibiotic activity was related to concentration, obeying the classical pharmacological model reported for all other antibiotics examined in this model so far. 7,9,21 Results showed that: (i) S. aureus displayed similar growth for all conditions (broth, THP-1 or HUVECs); (ii) torezolid and linezolid had a similar relative efficacy ($0.5 -1.5 log 10 cfu decrease) at equivalent multiples of the MIC; (iii) torezolid and linezolid significantly differed with respect to their relative potencies if data are plotted against drug weight concentrations (mg/L) but not if expressed as multiples of the corresponding MIC; and (iv) both torezolid and linezolid showed a slightly but significantly higher relative efficacy (lower E max ) in HUVECs compared with THP-1 cells.
Susceptibility testing
Susceptibility of intracellular forms (THP-1) of S. aureus with different resistance phenotypes
Comparative 24 h concentration -response studies were then performed using the strain ATCC 25923 and four methicillinresistant S. aureus (MRSA) strains chosen for being either susceptible (NRS 384 and SA 238) or resistant (CM 05 and SA 238L) to linezolid. Results are presented in Figure 4 with drug concentrations shown as multiples of the MIC ( pharmacological comparison). This shows that all strains behaved similarly when exposed to either torezolid or linezolid over the wide range of concentrations explored. Although statistical analysis showed that the functions describing the concentration -response effects are significantly different (see numeric values in the figure legend), these differences were minor and affected in an opposite way the relative potencies (EC 50 ) and relative efficacies (E max ) of each drug. Of note, a different picture would emerge, however, if data are plotted as a function of the weight concentrations of the antibiotics, in which case the relative potencies (EC 50 ) and the static concentrations (C s ) of the corresponding 
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antibiotics would be widely different and in relation to the differences in MIC of the organisms tested.
Susceptibility of intraphagocytic forms of L. monocytogenes and L. pneumophila
In these experiments, we examined the behaviour of torezolid and linezolid towards other organisms that could live and multiply in compartments other than phagolysosomes. Concentration -effect studies were therefore performed with phagocytosed L. monocytogenes and L. pneumophila (see MICs in Table 1 ). As seen in Figure 5 , torezolid and linezolid again showed concentration-dependent activities against both phagocytosed organisms, with no significant differences in relative potencies (EC 50 parameter), static concentrations (C s ) and relative efficacies (E max ) when data were plotted against equipotent drug concentrations (multiples of the MIC). As for S. aureus, however, plotting the data as a function of the weight concentration revealed differences in relative potencies and static concentrations that essentially matched the differences in MIC.
Discussion
Intracellular survival of bacteria remains an important cause of bacterial spread, life-threatening therapeutic failures, and persistence of infection in spite of apparently effective antimicrobial therapy as far as in vitro activity is concerned. 22, 23 This may be of direct application to linezolid, as this drug shows poor activity against intracellular forms of bacteria in models in which extracellular and intracellular activities have been directly compared.
7,17
The present study expands our knowledge of the role played by intracellular accumulation of antibiotics in general, and of oxazolidinones in particular in two main respects. First, we showed that the intracellular accumulation of oxazolidinones may differ, since torezolid concentrates $10-fold in cells under conditions in which linezolid showed only a modest accumulation. This accumulation is largely reduced by exposure to acid pH, suggesting that it could depend upon the cellular to extracellular pH gradient, as observed with macrolides 24, 25 and weak basic drugs in general. 26, 27 Yet torezolid is probably not a weaker basic drug than linezolid, based on its calculated physicochemical properties (see legend of Figure 1 ), indicating that properties other than their basic character may be more critical. These may include the ratios of the membrane permeability coefficients of the unionized and ionized forms of the two molecules, or their ability to bind to cellular constituents. While membrane diffusion, cell fractionation and morphological studies would be most useful in this context, these could not be undertaken to date due to lack of sufficiently sensitive and specific methods for differential assay or visualization of intracellular torezolid and linezolid.
Secondly, we showed that torezolid: (i) expresses a higher relative antibiotic potency than linezolid (lower values for the EC 50 and C s pharmacodynamic parameters) as long as concentrations are expressed as a weight basis, but not when they are expressed as multiples of the MIC; and (ii) shows essentially a similar maximal efficacy when compared with linezolid (no significant difference in the E max pharmacodynamic Table 2 . Pertinent regression parameters of the dose -responses curves illustrated in Figure 3 parameter). This indicates that the main if not exclusive driver of intracellular activity for torezolid in comparison with linezolid with respect to its relative potency is its higher intrinsic activity (as denoted by a lower MIC), whereas its greater accumulation plays no detectable role. The data also show that the two drugs remain similar with respect to their level of maximal activity, suggesting a similar mode of action. Thus, torezolid keeps the essentially bacteriostatic character of linezolid (as the maximal efficacies of both drugs in all conditions never exceed $1 log 10 cfu decrease over the original inoculum). It is important to note that the similarity of behaviour between torezolid and linezolid, when data are expressed as a function of multiples of their MIC, is observed over a wide range of concentrations, and is, therefore, likely to correspond to true intrinsic pharmacological properties of the molecules. The fact that accumulation of torezolid seems not to play a significant role in its activity is probably unrelated to a specific subcellular localization (which, as indicated above, remains to be established) and/or physicochemical environment. Indeed, similar results are observed with the three organisms studied with respect to the key role of MIC as a driver of activity, even though each of them localizes and multiplies in a distinct subcellular compartment, namely the cytosol 28, 29 (where pH is close to neutrality) for L. monocytogenes, phagosomes and weakly acidic vacuoles for L. pneumophila, 30 and phagolysosomes and acidic vacuoles for S. aureus in macrophages. 11, 31 Interestingly enough, this is also seen for S. aureus in HUVECs, although bacterial localization in these cells involves both the cytosol and the phagolysosomes 32 (confirmed in our experimental conditions). 33 This could explain the higher relative intracellular efficacy (lower E max ) observed in these cells compared with THP-1 macrophages.
Pending further investigations, the present study strongly suggests that the accumulation of torezolid is quantitatively offset by a commensurate decrease in its activity in the intracellular milieu. This surprising situation is actually not specific to oxazolidinones, as it exactly parallels what we observed earlier for fluoroquinolones, and moxifloxacin in particular (see data and discussions in Carryn et al., 12 and in Seral et al.
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and Barcia-Macay et al. 7 ) in the same models of L. monocytogenes-and S. aureus-infected THP-1 cells. Thus, whereas moxifloxacin accumulates $6-to 20-fold in these cells, 35 quantitative analysis shows that its relative potency is similar to that exerted against extracellular bacteria, as if the intracellular concentration of the bioavailable drug was limited to that of the extracellular concentration.
At this point, it nevertheless remains obvious that torezolid exerts intracellular antimicrobial activities that are superior to linezolid, in terms of relative potency, when used at the same weight concentration. This may lead to improved therapy of intracellular infections provided that the modifications made to obtain torezolid from the oxazolidinone scaffold do not adversely alter its safety profile and allow its use in patients under conditions creating extracellular concentrations similar to those of linezolid or, at least, maintaining a higher concentration/MIC ratio. Animal studies may be helpful to further substantiate this hypothesis, as they will be able to take into account a series of parameters that cannot be included in our model but are also critical, such as serum protein and tissue binding, inoculum effects, influence of the scheme of administration and host defences.
